Fingerprint
Dive into the research topics of 'Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically